Hidradenitis suppurativa (HS) Learning Zone
Transcript: Impact of targeted treatments in HS
Dr Thrasyvoulos Tzellos
Interview recorded Sep 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So, it was very interesting to see new data coming from the important clinical trials in hidradenitis suppurativa. And recently we had two approved treatments, bimekizumab and secukinumab, and which inhibit interleukin-17. And regarding bimekizumab, we saw more data regarding a long-term effect.
We saw the long-term positive effect on draining fistulas, with a clinical important reduction compared to placebo, which remained in the long term. We saw achievement of many important patient reported outcomes in the long term, especially when it comes to pain, itch, odour which are important symptoms in HS for our patients. We saw data also for the higher level of achievement for IHS4, up to 90% in the long term. When it comes to secukinumab, we saw the same data and long-term effect with a nice safety profile. A nice safety profile when it comes to Candida infections as well. And it was important to see also the effect of secukinumab on cardiovascular risk parameters.
So, it was shown that secukinumab significantly reduced high sensitive CRP and also, it did not have any negative impact on other important cardiovascular disease risks. When it comes to new agents now, exciting data regarding sonelokimab and interleukin-17 inhibitor as well, inhibiting both interleukin-17A and F like bimekizumab does. And we saw from the MIRA 24 weeks report from the phase two programme, significant effect in IHS4 90, but also 100, which practically means a remission of all inflammatory lesions of HS, along with a very positive effect on many important patient reported outcomes up to week to week 24. Furthermore, the interesting data regarding the phase 2 upadacitinib programme, a JAK inhibitor, which showed significant effect in achievement of IHS4 up to 90 and the high score up to 90.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently by Medthority who previously received educational funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.